OTTAWA, Jan. 6, 2017 /CNW/ - Health Canada has conducted a safety review of gadolinium-based contrast agents (GBCAs) due to growing scientific evidence that gadolinium may accumulate in the brain ...
LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it has launched Gadoterate Meglumine Injection, USP, a bioequivalent and therapeutic equivalent substitute for the contrast agent ...
Approval marks a major milestone in reducing gadolinium exposure while maintaining diagnostic performance, aligning with clinical guidance to use the lowest effective dose MONTREAL, April 17, 2026 ...
The FDA has granted expanded indications for use of gadobutrol (Gadavist; Bayer) injection, permitting its use in cardiac MR to assess myocardial perfusion and late gadolinium enhancement in adults ...
CHALFONT ST GILES, England--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has approved Clariscan™, a macrocyclic, ionic, gadolinium-based, MRI contrast agent, expanding the GE ...
New research finds direct evidence of gadolinium deposition in neuronal tissues following intravenous administration of gadolinium-based contrast agents used in MRI exams. "Despite evidence that trace ...
Approval expands low-dose MRI contrast options for the youngest patients and reflects a positive benefit–risk profile of VUEWAY® injection from birth through adulthood PRINCETON, N.J., Feb. 23, 2026 ...
The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Wanda Milley seldom ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results